Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation.
Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M, Genotype to Phenotype Japan (G2P-Japan) Consortium, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. · 2022
Read Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. by Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M, Genotype to Phenotype Japan (G2P-Japan) Consortium, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8828475.txt.
Introduction
Saito and co-authors dissect what made the SARS-CoV-2 Delta variant more dangerous. Delta drove a huge COVID-19 surge in India in spring 2021. Its viral traits, though, were poorly understood. The team focused on one spike change, P681R. That change is nearly always present in this lineage. They tested the variant and the single mutation in cells and hamsters.
Delta proved highly fusogenic, meaning its cells merge readily. The P681R change eased cutting of the spike protein. That cutting step boosted the merging behavior. Viruses carrying P681R also caused worse disease than their parent virus. The authors name P681R a hallmark of Delta. They link it directly to the variant's added harm.
Catalog record
| CREATOR | Saito A, Irie T, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Loeber S, Tsuda M, Wang L, Ozono S, Butlertanaka EP, Tanaka YL, Shimizu R, Shimizu K, Yoshimatsu K, Kawabata R, Sakaguchi T, Tokunaga K, Yoshida I, Asakura H, Nagashima M, Kazuma Y, Nomura R, Horisawa Y, Yoshimura K, Takaori-Kondo A, Imai M, Genotype to Phenotype Japan (G2P-Japan) Consortium, Tanaka S, Nakagawa S, Ikeda T, Fukuhara T, Kawaoka Y, Sato K. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation By Akatsuki Saito, Takashi Irie, Rigel Suzuki, Tadashi Maemura, Hesham Nasser, Keiya Uriu, Yusuke Kosugi, Kotaro Shirakawa, Kenji Sadamasu, Izumi Kimura, Jumpei Ito, Jiaqi Wu Published in: Nature DOI: 10.1038/s41586-021-04266-9 ABSTRACT During the current coronavirus disease 2019 (COVID-19) pandemic, a variety of mutations have accumulated in the viral genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, at the time of writing, four variants of concern are considered to be potentially hazardous to human society1. The recently emerged B.1.617.2/Delta variant of concern is closely associated with the COVID-19 surge that occurred in India in the spring of 2021 (ref. 2). However, the virological properties of B.1.617.2/Delta remain unclear. Here we show that the B.1.617.2/Delta variant is highly fusogenic and notably more pathogenic than prototypic SARS-CoV-2 in infected hamsters. The P681R mutation in the spike protein, which is highly conserved in this lineage, facilitates cleavage of the spike protein and enhances viral fusogenicity. Moreover, we demonstrate that the P681R-bearing virus exhibits higher pathogenicity compared with its parental virus. Our data suggest that the P681R mutation is a hallmark of the virological phenotype of the B.1.617.2/Delta variant and is associated with enhanced pathogenicity. MAIN During the current pandemic, SARS-CoV-2 has acquired a variety of mutations3. First, in spring 2020, a SARS-CoV-2 derivative containing a D614G mutation in its spike (S) protein emerged and quickly became predominant4. As the D614G mutation increases viral infectivity, fitness and interindividual transmissibility5–10, the D614G-bearing variant quickly outcompeted the original strain. Since autumn 2020, some SARS-CoV-2 variants bearing multiple mutations have emerged and spread rapidly worldwide. As of September 2021, four variants of concern (VOCs) had emerged: B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma) and B.1.617.2 (Delta)11,12. The B.1.617 lineage emerged in India at the end of 2020 and is thought to have been a major driver of the massive COVID-19 surge in India that peaked at 400,000 infection cases per day2. The B.1.617 lineage includes three sublineages—B.1.617.1, B.1.617.2 and B.1.617.3. Sublineage B.1.617.2 was defined as the latest VOC as of 25 November 2021, the Delta variant11,12. Importantly, early evidence has suggested that infection with B.1.617.2/Delta may carry an increased risk of hospitalization compared with infection with B.1.1.7 (refs. 13–15). However, the virological features of this newly emerging VOC, particularly its infectivity and pathogenicity, remain unclear. In this study, we demonstrate that B.1.617.2/Delta is more pathogenic than the prototypic SARS-CoV-2 in a Syrian hamster model. We also show that the P681R mutation in the S protein is a hallmark mutation of this lineage. The P681R mutation enhances the cleavage of the SARS-CoV-2 S protein and enhances viral fusogenicity. Moreover, we demonstrate that the P681R mutation can partly explain the higher pathogenicity of the B.1.617.2/Delta variant in vivo. EPIDEMIC DYNAMICS OF THE B.1.617 LINEAGE We set out to investigate the phylogenetic relationships of the three subvariants belonging to the B.1.617 lineage. We downloaded 1,761,037 SARS-CoV-2 genomes and corresponding data from the Global Initiative on Sharing All Influenza Data (GISAID) database (https://www.gisaid.org; as of 31 May 2021). As expected, each of the three sublineages B.1.617.1, B.1.617.2 and B.1.617.3 formed a monophyletic cluster (Fig. 1a and Extended Data Fig. 1). We next analysed the epidemic dynamics of each of the three B.1.617 sublineages. The B.1.617 variant, specifically B.1.617.1, was first detected in India on 1 December 2020 (GISAID ID: EPI_ISL_1372093) (Fig. 1b, c).Fig. 1Molecular phylogenetics and epidemic dynamics of the B.1.617 lineage pandemic.a, Phylogenetic tree of the B.1.617 lineage. Scale bar, 0.0002 substitutions per site. Bootstrap values are indicated by asterisks; **100%, *>70%. The uncollapsed tree is shown in Extended Data Fig. 1. b, c, Epidemic dynamics of the B.1.617 lineage. b, The number of sequences deposited in GISAID per day for India (top), the UK (middle) and the world (bottom). c, The percentages of each lineage deposited per day from India (orange), the UK (blue) and the world (grey). The date on which each variant was first identified is indicated. The raw data are summarized in Supplementary Table 1. d, The proportion of amino acid replacements in the B.1.617 lineage. The top 10 replacements conserved in the S protein of B.1.617 and its sublineages are summarized. The numbers in parentheses indicate the number of sequences included in each panel. The raw data are summarized in Supplementary Table 2. B.1.617.2 (GISAID ID: EPI_ISL_2131509) and B.1.617.3 (GISAID IDs: EPI_ISL_1703672, EPI_ISL_1703659 and EPI_ISL_1704392) were detected in India on 10 December 2020 and 13 February 2021, respectively (Fig. 1c). The prevalence of the B.1.617.1 sublineage peaked from February to April 2021 in India and then decreased (Fig. 1c). Although the B.1.617.3 variant has been detected sporadically in India, the B.1.617.2/Delta lineage has been dominant in India since March 2021 and has also spread all over the world (Fig. 1c). At the end of May 2021, 100%, 70% and 43.3% of the sequences deposited in GISAID per day from India (May 7), the UK (May 21) and the world (May 19), respectively, were B.1.617.2 sublineage sequences (Fig. 1c and Supplementary Table 1). We next investigated the proportion of amino acid replacements in the S protein of each B.1.617 sublineage compared with the reference strain (Wuhan-Hu-1; GenBank: NC_045512.2). As shown in Fig. 1d, the L452R and P681R mutations were highly conserved in the B.1.617 lineage and, notably, the P681R mutation (16,650 out of 16,759 sequences, 99.3%) was the most representative mutation in this lineage. These data suggest that the P681R mutation is a hallmark of the B.1.617 lineage. SYNCYTIUM FORMATION BY THE DELTA VARIANT To investigate the virological characteristics of the B.1.617.2/Delta variant, we conducted virological experiments using an isolate of B.1.617.2 (GISAID ID: EPI_ISL_2378732) as well as a D614G-bearing B.1.1 isolate (GISAID ID: EPI_ISL_479681) in Japan. In Vero cells, the growth of the B.1.617.2/Delta variant was significantly lower compared with the growth of the B.1.1 isolate (Fig. 2a). In particular, the viral RNA levels of the B.1.617.2/Delta variant at 48 h post-infection (h.p.i.) were more than 150-fold lower than those of the B.1.1 isolate (Fig. 2a). By contrast, although the growth kinetics of these viruses were relatively comparable in VeroE6/TMPRSS2 cells and Calu-3 cells (Fig. 2a), microscopy observations showed that the B.1.617.2/Delta variant formed larger syncytia than the B.1.1 virus (Fig. 2b). Measurements of the sizes of the floating syncytia in the infected VeroE6/TMPRSS2 culture indicated that the syncytia stimulated by B.1.617.2/Delta infection were significantly (3.6-fold) larger than those stimulated by B.1.1 infection (Fig. 2b). Moreover, the plaque size in VeroE6/TMPRSS2 cells infected with B.1.617.2/Delta was significantly larger (1.2-fold) compared with in VeroE6/TMPRSS2 cells infected with B.1.1 virus (Extended Data Fig. 2a). Immunofluorescence assays further showed that B.1.617.2/Delta-infected VeroE6/TMPRSS2 cells exhibited larger multinuclear syncytia compared with B.1.1-infected cells (Extended Data Fig. 3a). Notably, although the B.1.1.7/Alpha and B.1.351/Beta VOCs also formed larger syncytia compared with B.1.1, the syncytia formed by B.1.617.2/Delta infection were 1.6-fold and 1.8-fold larger than those formed by B.1.1.7/Alpha and B.1.351/Beta infections, respectively, with statistical significance (Fig. 2b). To directly assess the fusogenicity of the S proteins of these variants, we performed a cell-based fusion assay. We verified that this assay requires expression of human ACE2 in the target cells (Extended Data Fig. 4a). Although the fusogenicity of S proteins of all VOCs